Abstract:Programmable epigenome editors modify gene expression in mammalian cells by altering the local chromatin environment at target loci without inducing DNA breaks. However, the large size of CRISPR-based epigenome editors poses a challenge to their broad use in biomedical research and as future therapies. Here, we present Robust ENveloped Delivery of Epigenome-editor Ribonucleoproteins (RENDER) for transiently delivering programmable epigenetic repressors (CRISPRi, DNMT3A-3L-dCas9, CRISPRoff) and activator (TET1-dCas9) as ribonucleoprotein complexes into human cells to modulate gene expression. After rational engineering, we show that RENDER induces durable epigenetic silencing of endogenous genes across various human cell types, including primary T cells. Additionally, we apply RENDER to epigenetically repress endogenous genes in human stem cell-derived neurons, including the reduction of the neurodegenerative disease associated V337M-mutated Tau protein. Together, our RENDER platform advances the delivery of CRISPR-based epigenome editors into human cells, broadening the use of epigenome editing in fundamental research and therapeutic applications.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop an efficient method for instantaneous delivery of CRISPR epigenome editors, in order to achieve precise regulation of target gene expression in mammalian cells. Specifically, the paper introduces a platform named RENDER (Robust ENveloped Delivery of Epigenome - editor Ribonucleoproteins), which utilizes engineered virus - like particles (eVLPs) to deliver CRISPR epigenome editor ribonucleoprotein complexes (RNPs), thereby achieving persistent epigenetic silencing or activation of target genes without causing DNA breaks. ### Main research questions: 1. **Improve the delivery efficiency of CRISPR epigenome editors**: Traditional CRISPR epigenome editors are difficult to be effectively delivered into cells through existing delivery systems (such as adeno - associated virus AAV) due to their large molecular weights. The RENDER platform solves this problem by using virus - like particles (VLPs), which can carry large CRISPR epigenome editors and do not pose the risk of viral genome integration. 2. **Achieve instantaneous and persistent epigenetic regulation**: The RENDER platform can not only instantaneously deliver CRISPR epigenome editors but also achieve persistent gene silencing in multiple human cell types. This is of great significance for both basic research and therapeutic applications, especially in scenarios where long - term suppression of disease - related gene expression is required. 3. **Optimize the delivery conditions of CRISPR epigenome editors**: The paper describes in detail how to optimize the delivery efficiency of CRISPR epigenome editors by adjusting the component ratios in eVLP (such as the ratio of gag - CRISPRoff to gag - pol), thereby achieving efficient gene silencing at lower doses. 4. **Expand the application range of CRISPR epigenome editing**: The RENDER platform not only shows good performance in common cell lines but also successfully achieves gene silencing in primary T cells and neurons derived from induced pluripotent stem cells (iPSC), demonstrating its potential applications in immunotherapy and the treatment of neurodegenerative diseases. ### Specific research contents: - **Construction of the RENDER platform**: Deliver CRISPR epigenome editors, including CRISPRi, DNMT3A - 3L - dCas9 and CRISPRoff, through engineered virus - like particles (eVLPs). - **Function verification**: Verify the function of the RENDER platform in HEK293T cells. Confirm the gene silencing effect by detecting the expression level of CLTA - GFP through flow cytometry. - **Optimization of delivery conditions**: Improve the delivery efficiency of CRISPRoff and the persistence of gene silencing by adjusting the ratio of gag - CRISPRoff to gag - pol and increasing the amount of sgRNA. - **Application in multiple cell types**: Verify the wide applicability of the RENDER platform in multiple human cell lines (such as HEK293T, HepG2, Jurkat, etc.). - **Large - scale cell engineering**: Prove that the RENDER platform can be used for large - scale cell engineering and is suitable for high - throughput CRISPR screening. - **Application in primary T cells and iPSC - derived neurons**: Achieve gene silencing in primary T cells and successfully suppress the expression of the MAPT gene in iPSC - derived neurons, reducing the level of Tau protein related to neurodegenerative diseases. In conclusion, this paper solves several key problems in the delivery of CRISPR epigenome editors by developing the RENDER platform, providing new tools and technical means for future gene regulation and therapeutic applications.

Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins

CRISPRoff epigenetic editing for programmable gene silencing in human cells without DNA breaks

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Programmable DNA Repair with CRISPRa/i Enhanced Homology-Directed Repair Efficiency with a Single Cas9

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

Engineering self-deliverable ribonucleoproteins for genome editing in the brain

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications

Programmable RNA base editing with photoactivatable CRISPR-Cas13

Advanced Peptide Nanoparticles Enable Robust and Efficient delivery of gene editors across cell types

CHARM and EvoETR: Precision epigenetic tools for gene silencing

Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells

Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing

Regulation of gene expression by altered promoter methylation using a CRISPR/Cas9-mediated epigenetic editing system

Tailoring a CRISPR/Cas-based Epigenome Editor for Programmable Chromatin Acylation and Decreased Cytotoxicity

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Discovery of hypercompact epigenetic modulators for persistent CRISPR-mediated gene activation

Durable and efficient gene silencing in vivo by hit-and-run epigenome editing

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Programmable RNA writing with trans-splicing